American Oriental Bioengineering, Inc. Reiterated ‘Buy/4,’ Target Valuation $6 By Investrend Analyst Kipley Lytel, CFA

NEW YORK--(BUSINESS WIRE)--Aug. 24, 2006--(Investrend Research Syndicate) American Oriental Bioengineering (AMEX: AOB) ‘Buy/4' rating and $6 target valuation reiterated in an Institutional Update by Investrend Research analyst Kipley Lytel, CFA.